Drug intelligence / Profile preview

Soluble Beta-Glucan

Development stage
Phase 3
Lead developer
Biotec Beta-Glucans
Administration
Oral, Intravenous, Topical
01

Overview

Soluble Beta-Glucan (SBG) is a polysaccharide derived from various natural sources, including yeast, fungi, cereals (oats, barley), and microalgae. It is recognized for its immunomodulatory properties, primarily by activating immune cells such as macrophages, neutrophils, monocytes, and natural killer cells through binding to specific receptors like Dectin-1 and Complement receptor 3 (CR3). This activation leads to the release of pro-inflammatory molecules and enhanced anti-microbial and anti-tumor activity. Beyond immune modulation, SBG also influences glucose metabolism by inhibiting α-glucosidase and Sodium/glucose cotransporter 1 (SGLT1), and by stimulating Glucagon-like peptide 1 (GLP-1) secretion indirectly through short-chain fatty acid production in the gut. It also exhibits antioxidant and anti-inflammatory effects. SBG is being investigated in clinical trials for a range of conditions, including various cancers (e.g., neuroblastoma, bladder cancer, non-Hodgkin's lymphoma, advanced solid tumors, gastric cancer, cervical cancer, head and neck cancers), infectious diseases (e.g., COVID-19), and metabolic disorders (e.g., type 1 diabetes, high cholesterol, diabetic foot ulcers, chronic leg ulcers in diabetes patients, obesity). Some forms, such as lentinan, are approved in certain Asian countries as adjuvants to chemotherapy. It is also widely available as a dietary supplement and used in nutraceuticals.

Brand names
Woulgan
Other names
Beta-glucanHighly Soluble Beta-GlucanGlucan sulfate
02

Targets

αMβ2 (Integrin αMβ2)SLC5A1 (Sodium Glucose Cotransporter 1)CLEC7A (Dectin-1)TLR2 (Toll-like Receptor 2)Sucrase-Isomaltase

Beyond the preview

Go deeper on Soluble Beta-Glucan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soluble Beta-Glucan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call